Boceprevir and Promacta (Eltrombopag Powder for Suspension)

In the database of official manuals used in the service creation an interaction registered by statistical results of studies was found, which can either lead to negative consequences for the patient health or strengthen a mutual positive effect. A doctor should be consulted to address the issue of joint drug administration.

Consumer information for this minor interaction is not currently available. Some minor drug interactions may not be clinically relevant in all patients. Minor drug interactions do not usually cause harm or require a change in therapy. However, your healthcare provider can determine if adjustments to your medications are needed.

Coadministration with eltrombopag may alter the pharmacokinetics of boceprevir. In 28 healthy volunteers administered a single 200 mg dose of eltrombopag during repeated dosing of boceprevir 800 mg three times daily, boceprevir systemic exposure (AUC) decreased by just 4% but trough plasma level (Cmin) decreased by 32%. The clinical significance is unknown, although the potential for more substantial changes during multiple dosing of eltrombopag cannot be ruled out. Boceprevir did not have an effect on the plasma concentrations of eltrombopag.

Boceprevir

Generic Name: boceprevir

Brand name: Victrelis

Synonyms: Boceprevir (Oral)

What is Boceprevir?

Promacta (Eltrombopag Powder for Suspension)

Generic Name: eltrombopag

Brand name: Promacta

Synonyms: Promacta

What is Promacta (Eltrombopag Powder for Suspension)?